Citigroup’s Regencell Bioscience RGC Stock Holding History

Citigroup’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6	Sell	1 -1,830	-100%	-$10.6K	﹤0.01%	5838
2026 Q2	$11.2K	Buy	1,831 +1,830	+183,000%	+$44K	﹤0.01%	5230
2026 Q1	$25	Buy	+1	New	+$28	﹤0.01%	5686
2025 Q3	–	Sell	-70	Closed	-$1.19K	–	6281
2025 Q2	$1.19K	Buy	+70	New	+$854	﹤0.01%	5397
2022 Q2	–	Sell	-85,120	Closed	-$48K	–	6583
2022 Q1	$48K	Buy	+85,120	New	+$73K	﹤0.01%	4744

Other funds holding RGC

CIBC Asset Management Toronto, Ontario, Canada $47B AUM 34.17% 1-Year Est. Return

Larson Financial Group St Louis, Missouri $4.11B AUM 23.62% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return

Bare Financial Services Gap, Pennsylvania $447M AUM 11.53% 1-Year Est. Return

Provenance Wealth Advisors Fort Lauderdale, Florida $1.69B AUM 11.53% 1-Year Est. Return

Silver Grove Financial Group Orchard Park, New York $214M AUM 19.83% 1-Year Est. Return

Bell Investment Advisors Oakland, California $684M AUM 11.42% 1-Year Est. Return

Mainstream Capital Management Los Angeles, California $170M AUM 21% 1-Year Est. Return

Citigroup's RGC Position: Q3 2026 in Review

Citigroup reduced its Regencell Bioscience (RGC) stake by 100% in Q3 2026, selling an estimated $10.6K and leaving 1 share worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #5838.

Citigroup first reported a position in RGC in Q1 2022 and has held it in 5 quarters since. The position peaked at $48K in Q1 2022. 9 funds tracked by Wall St. Rank hold RGC as of Q3 2026.

Citigroup held 1 share of Regencell Bioscience worth $6 as of Q3 2026.
Citigroup sold 1,830 Regencell Bioscience shares in Q3 2026, an estimated $10.6K.
Regencell Bioscience made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5838 holding.
Citigroup first reported a position in Regencell Bioscience in Q1 2022 and has held it in 5 quarters since.
Citigroup's Regencell Bioscience position peaked at $48K in Q1 2022.
9 funds tracked by Wall St. Rank held Regencell Bioscience as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.